Stock report · Delisted · Nasdaq
Histogen Inc (HSTO)
0.03USD Delisted Final close · Jan 7, 2025
HSTO no longer trades. Histogen was delisted from the Nasdaq in January 2025.
All prices on this page are historical. The last trade was on January 7, 2025, at $0.03.
HSTO stock price history
Final trading statistics
- Final close
- $0.03
- Final trading day
- Jan 7, 2025
- Market cap at delisting
- $118.3K
- Shares outstanding
- 4.27M
- Final 52-week range
- $0.02 – $0.55
- Avg. volume (final 3 mo.)
- 1,328
- All-time high
- $2850.00 · Jan 2014
- All-time low
- $0.02 · Nov 2024
- Return since IPO
- -100.0%
- Beta
- 1.12
- Book value / share
- $1.27
- Price / book
- 0.02
About Histogen Inc
Histogen Inc. was a clinical-stage company developing small molecule pan-caspase and caspase-selective inhibitors meant to support the body's natural process of restoring immune function. Its candidate emricasan targeted acute bacterial skin and skin structure infections and other infectious diseases.
Preclinical candidates CTS-2090 and CTS-2096 were selective caspase-1 inhibitors aimed at inflammatory diseases. Founded in 2007 and based in San Diego, California, the company filed for Chapter 11 reorganization in the U.S. Bankruptcy Court for the Southern District of California on April 18, 2024.
Its shares were delisted from the Nasdaq in January 2025, with the last trade on January 7, 2025 at $0.03.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- San Diego, CA
- Employees
- 7
- IPO date
- July 25, 2013
- Delisted
- January 7, 2025
- SEC CIK
- 1383701
Histogen financials before the delisting
The last 5 fiscal years Histogen reported as a public company, fiscal year ending December.
HSTO revenue and net income
HSTO earnings per share
HSTO annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $19.0K | −$12.4M | — |
| FY2022 | $3.77M | −$10.5M | −$3.37 |
| FY2021 | $919.0K | −$14.4M | −$8.00 |
| FY2020 | $2.06M | −$25.8M | −$42.00 |
| FY2019 | $11.30M | −$4.9M | −$52.80 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Histogen stock FAQ
What happened to Histogen stock?
Histogen was delisted from the Nasdaq in January 2025. The final close was $0.03 on January 7, 2025.
Can I still buy HSTO stock?
No. HSTO is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on January 7, 2025.
What was the last price of HSTO?
HSTO last closed at $0.03 on January 7, 2025, which valued the company at about $118.3K.
How did Histogen do in its last full fiscal year?
In fiscal 2023, its last full year as a public company, Histogen reported revenue of $19.0K and net income of −$12.4M.
When did Histogen go public?
Histogen shares started trading on July 25, 2013.
HSTO no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.